Crizotinib is an oral MET/ALK inhibitor used as first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements and has shown striking efficiency against ALK-rearranged NB, both in mouse models and in patients3, 22, 23. This evidence concerns the gene ALK and neuroblastoma.